Market Cap
US$71.0m
Last Updated
2020/07/03 00:21 UTC
Data Sources
Company Financials +
Executive Summary
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States.
Snowflake Analysis
High growth potential with adequate balance sheet.
Share Price & News
How has SCYNEXIS's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SCYX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.5%
SCYX
1.4%
US Pharmaceuticals
1.6%
US Market
1 Year Return
-44.3%
SCYX
-0.3%
US Pharmaceuticals
4.8%
US Market
Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned -0.3% over the past year.
Return vs Market: SCYX underperformed the US Market which returned 4.8% over the past year.
Shareholder returns
| SCYX | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.5% | 1.4% | 1.6% |
| 30 Day | -10.8% | -2.6% | 2.3% |
| 90 Day | -11.2% | 9.0% | 29.5% |
| 1 Year | -44.3%-44.3% | 2.3%-0.3% | 7.1%4.8% |
| 3 Year | -60.5%-60.5% | 24.2%15.1% | 37.1%28.1% |
| 5 Year | -92.0%-92.0% | 27.9%13.3% | 67.2%48.6% |
Price Volatility Vs. Market
How volatile is SCYNEXIS's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
The SCYNEXIS (NASDAQ:SCYX) Share Price Is Down 90% So Some Shareholders Are Rather Upset1 month ago | Simply Wall St
How Much Are SCYNEXIS, Inc. (NASDAQ:SCYX) Insiders Spending On Buying Shares?2 months ago | Simply Wall St
What Kind Of Shareholders Own SCYNEXIS, Inc. (NASDAQ:SCYX)?Valuation
Is SCYNEXIS undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SCYX ($0.72) is trading below our estimate of fair value ($11.82)
Significantly Below Fair Value: SCYX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SCYX is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: SCYX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SCYX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SCYX is overvalued based on its PB Ratio (10.9x) compared to the US Pharmaceuticals industry average (3.3x).
Next Steps
Future Growth
How is SCYNEXIS forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
73.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SCYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: SCYX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SCYX's is expected to become profitable in the next 3 years.
Revenue vs Market: SCYX's revenue (74.6% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: SCYX's revenue (74.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SCYX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has SCYNEXIS performed over the past 5 years?
-10.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SCYX is currently unprofitable.
Growing Profit Margin: SCYX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SCYX is unprofitable, and losses have increased over the past 5 years at a rate of -10.4% per year.
Accelerating Growth: Unable to compare SCYX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCYX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).
Return on Equity
High ROE: SCYX has a negative Return on Equity (-585.65%), as it is currently unprofitable.
Next Steps
Financial Health
How is SCYNEXIS's financial position?
Financial Position Analysis
Short Term Liabilities: SCYX's short term assets ($36.8M) exceed its short term liabilities ($7.1M).
Long Term Liabilities: SCYX's short term assets ($36.8M) exceed its long term liabilities ($28.0M).
Debt to Equity History and Analysis
Debt Level: SCYX's debt to equity ratio (133.2%) is considered high.
Reducing Debt: Insufficient data to determine if SCYX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SCYX has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: SCYX is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.
Next Steps
Dividend
What is SCYNEXIS current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SCYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SCYX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SCYX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SCYX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SCYX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.7yrs
Average management tenure
CEO
Marco Taglietti (60yo)
5.25yrs
Tenure
US$1,534,585
Compensation
Dr. Marco Taglietti, M.D., has been the Chief Executive Officer of SCYNEXIS, Inc. since April 1, 2015 and has been President since September 24, 2015. He served as an Independent Director of Delcath System ...
CEO Compensation Analysis
Compensation vs Market: Marco's total compensation ($USD1.53M) is above average for companies of similar size in the US market ($USD606.53K).
Compensation vs Earnings: Marco's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.25yrs | US$1.53m | 0.70% $499.5k | |
| Chief Financial Officer | 4.67yrs | US$884.06k | 0.051% $36.2k | |
| Chief Medical Officer | 5.08yrs | US$1.01m | 0.15% $108.2k | |
| General Counsel & Corporate Secretary | 2.67yrs | no data | 0.0030% $2.1k | |
| Vice President of Marketing & Sales | 0.50yr | no data | no data |
4.7yrs
Average Tenure
50yo
Average Age
Experienced Management: SCYX's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.25yrs | US$1.53m | 0.70% $499.5k | |
| Independent Director | 1.5yrs | US$107.27k | no data | |
| Independent Director | 4.83yrs | US$90.21k | 0.032% $22.9k | |
| Independent Director | 11.58yrs | US$90.21k | 0.0043% $3.0k | |
| Independent Chairman of the Board | 5.08yrs | US$108.71k | 0.040% $28.8k | |
| Independent Director | 5.42yrs | US$91.96k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: SCYX's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 84.2%.
Top Shareholders
Company Information
SCYNEXIS, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: SCYNEXIS, Inc.
- Ticker: SCYX
- Exchange: NasdaqGM
- Founded: 1999
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$71.046m
- Shares outstanding: 98.81m
- Website: https://www.scynexis.com
Number of Employees
Location
- SCYNEXIS, Inc.
- 1 Evertrust Plaza
- 13th Floor
- Jersey City
- New Jersey
- 07302-6548
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SCYX | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | May 2014 |
| 135 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2014 |
| 0L49 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 2014 |
Biography
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/03 00:21 |
| End of Day Share Price | 2020/07/02 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.